Non-small cell lung cancer, version 5.2017, NCCN Clinical Practice Guidelines in Oncology Journal Article
| Authors: | Ettinger, D. S.; Wood, D. E.; Aisner, D. L.; Akerley, W.; Bauman, J.; Chirieac, L. R.; D'Amico, T. A.; Decamp, M. M.; Dilling, T. J.; Dobelbower, M.; Doebele, R. C.; Govindan, R.; Gubens, M. A.; Hennon, M.; Horn, L.; Komaki, R.; Lackner, R. P.; Lanuti, M.; Leal, T. A.; Leisch, L. J.; Lilenbaum, R.; Lin, J.; Loo, B. W., Jr.; Martins, R.; Otterson, G. A.; Reckamp, K.; Riely, G. J.; Schild, S. E.; Shapiro, T. A.; Stevenson, J.; Swanson, S. J.; Tauer, K.; Yang, S. C.; Gregory, K.; Hughes, M. |
| Article Title: | Non-small cell lung cancer, version 5.2017, NCCN Clinical Practice Guidelines in Oncology |
| Abstract: | This selection from the NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) focuses on targeted therapies and immunotherapies for metastatic NSCLC, because therapeutic recommendations are rapidly changing for metastatic disease. For example, new recommendations were added for atezolizumab, ceritinib, osimertinib, and pembrolizumab for the 2017 updates. © JNCCN-Journal of the National Comprehensive Cancer Network. |
| Journal Title: | Journal of the National Comprehensive Cancer Network |
| Volume: | 15 |
| Issue: | 4 |
| ISSN: | 1540-1405 |
| Publisher: | Harborside Press |
| Date Published: | 2017-04-01 |
| Start Page: | 504 |
| End Page: | 535 |
| Language: | English |
| PROVIDER: | scopus |
| PUBMED: | 28404761 |
| DOI/URL: | |
| Notes: | Review -- Export Date: 2 May 2017 -- Source: Scopus |
